Advice
In the absence of a submission from the holder of the marketing authorisation.
loteprednol etabonate 5mg/ml eye drops (Lotemax 0.5% eye drops, suspension) are not recommended for the treatment of post-operative inflammation following ocular surgery.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice51KB (PDF)
Medicine details
- Medicine name:
- loteprednol etabonate 0.5% 5mg/ml (Lotemax 0.5% eye drops suspension)
- SMC ID:
- 484/08
- Indication:
- for the treatment of post-operative inflammation following ocular surgery
- Pharmaceutical company
- Bausch and Lomb GmbH
- BNF chapter
- Eye
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 June 2008